Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

What is the purpose of this trial?

Brief Summary:

A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin


Participation Guidelines

Ages: 6 - 17 years

Gender: Both


Zealand Pharma A/S

Start Date: 01/29/2019

End Date: 07/01/2019

Last Updated: 03/25/2019

Study HIC#: 2000024075

Get Involved

For more information about this study, contact:
Kristen Kraemer
+1 631-275-8634
kristen.kraemer@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Eda Cengiz

Principal Investigator

Sub-Investigators